基本情報/Basic Information

開講科目名 ／Class	海外の薬剤師に学ぶⅢ／Learning from Foreign Pharmacists Ⅲ
授業コード ／Class Code	B404611001
開講キャンパス ／Campus	ﾎﾟｰﾄｱｲﾗﾝﾄﾞ
開講所属 ／Course	薬学部／Pharmaceutical Sciences
年度 ／Year	2023年度／Academic Year
開講区分 ／Semester	後期集中／AUTUMN INTENSIVE
曜日・時限 ／Day, Period	他(後期)／OTHERS(AUT.)
単位数 ／Credits	1.0
主担当教員 ／Main Instructor	辻本　貴江／TSUJIMOTO TAKAE
科目区分 ／Course Group	【専門教育科目】　《選択科目》／*** MAJORS *** 《ELECTIVE》
遠隔授業 ／Remote lecture	No

担当教員情報/Instructor Information

教員名 ／Instructor	教員所属名 ／Affiliation
久米　典昭／KUME NORIAKI	薬学部／Pharmaceutical Sciences
辻本　貴江／TSUJIMOTO TAKAE	薬学部／Pharmaceutical Sciences

授業の方法 ／Class Format	講義,演習
授業の目的 ／Class Purpose	この授業の担当者は薬学部所属であり、この科目は、アドバンスト科目であり１年次から6年次に配当している。 この科目は、学部のDPに示す８項目のうち、１、6を目指す。 ディプロマ・ポリシー（学位授与の方針） なお、この授業の担当者の1人は薬局・病院での薬剤師として実務経験のある教員であり、より実践的な観点からGlobal Pharmacy Practiceについて解説するものとする。 ① The goals of this course are to provide students with an overview of the clinical pharmacology of select immunotherapies that are used to treat common autoimmune diseases. ② The goals of this course are to provide students with an understanding of how to deliver pharmaceutical care in patients with osteoarthritis and gout. ③ The goals of this course are to provide students with a basic understanding of select women’s health topics including the use of contraceptive methods, appropriate prenatal care, management of select disorders in patients who are pregnant, and the effect of drugs on pregnancy and lactation. ④ The goals of this course are to provide students with basic understanding of the management of patients with rheumatoid arthritis, Crohn’s disease and ulcerative colitis, and psoriasis and psoriatic arthritis.
到　達　目　標 ／Class Objectives	① Clinical Pharmacology of Immunotherapies ② Pharmaceutical Care in Patients with Osteoarthritis and Gout ③ Pharmacotherapeutic Considerations in Select Women’s Health Topics ④ Pharmacotherapy of Select Immune Disorders AD-B-④-1 諸外国における薬局の機能と業務について、日本と比較しながら説明できる。 AD-B-⑤-1 地域社会における保健、医療、福祉の現状と問題点を調査し、地域による違いについて討議する。 AD-B-⑤-2 諸外国における薬剤師の活動分野について、日本と比較しながら説明できる。 JB-(3)-①-1 科学、医療に関連する英語の代表的な用語を列挙し、その内容を説明できる。 JB-(3)-①-2 科学、医療に関して英語で書かれた文章を読んで、内容を説明できる。 JB-(3)-②-2 自然科学各分野における基本的単位、数値、現象の英語表現を列記できる。 JB-(3)-②-3 科学、医療に関連する英語の代表的な用語、英語表現を列記できる。 JB-(3)-②-4 科学、医療に関連する簡単な文章を英語で書くことができる。 JB-(3)-③-1 英語の基礎的音声を聞き分けることができる。 JB-(3)-③-2 英語の会話を聞いて内容を理解して要約できる。 JB-(3)-③-3 英語による簡単なコミュニケーションができる。 JB-(3)-③-4 科学、医療に関連する代表的な用語を英語で発音できる。
授業のキーワード ／Keywords	Clinical Pharmacology、Immunotherapies、Osteoarthritis、Gout、Women’s Health 、Immune Disorders
授業の進め方 ／Method of Instruction	articipate in lecture, discussion, and active learning activities.
履修するにあたって ／Instruction to Students	事前に講義で使用する資料をドットキャンパスまたはOneDriveにアップロードします。
授業時間外に必要な学修 ／Expected Work outside of Class	事前学習として、資料に目を通しておくこと（目安として１時間）。
提出課題など ／Quiz,Report,etc
成績評価方法・基準 ／Grading Method・Criteria	講義ごとの小テスト（100%)
テキスト ／Required Texts
参考図書 ／Reference Books

No.	回 ／Time	主題と位置付け ／Subjects and position in the whole class	学習方法と内容 ／Methods and contents	備考 ／Notes
1	第1回	Clinical Pharmacology of ImmunotherapiesⅠ	Lecture and discussion on the following topics: Overview of the major components of the immune reaction and sites of drug action. Major pharmacologic action, adverse effects, and drug interactions of prototype drugs representing glucocorticosteroids, antimetabolites, antimalarials, aminosalicylates, JAK inhibitors, PDE-4 inhibitors, TNF inhibitors, T cell costimulation modulator, IL-12 / IL-23 and IL-23 antagonists, and CD20 antibody. Brief overview of other small drug immunotherapies (retinoids, calcineurin inhibitors) and biologic immunotherapy (α4β7 integrin blocker). AD-B-④-1、AD-B-⑤-1、AD-B-⑤-2、JB-(3)-①-1、JB-(3)-①-2、JB-(3)-②-1、JB-(3)-②-2、JB-(3)-②-3、JB-(3)-②-4、JB-(3)-③-1、JB-(3)-③-2、JB-(3)-③-3、JB-(3)-③-4
2	第2回	Clinical Pharmacology of ImmunotherapiesⅡ	Lecture and discussion on the following topics: Overview of the major components of the immune reaction and sites of drug action. Major pharmacologic action, adverse effects, and drug interactions of prototype drugs representing glucocorticosteroids, antimetabolites, antimalarials, aminosalicylates, JAK inhibitors, PDE-4 inhibitors, TNF inhibitors, T cell costimulation modulator, IL-12 / IL-23 and IL-23 antagonists, and CD20 antibody. Brief overview of other small drug immunotherapies (retinoids, calcineurin inhibitors) and biologic immunotherapy (α4β7 integrin blocker). AD-B-④-1、AD-B-⑤-1、AD-B-⑤-2、JB-(3)-①-1、JB-(3)-①-2、JB-(3)-②-1、JB-(3)-②-2、JB-(3)-②-3、JB-(3)-②-4、JB-(3)-③-1、JB-(3)-③-2、JB-(3)-③-3、JB-(3)-③-4
3	第3回	Pharmaceutical Care in Patients with Osteoarthritis and GoutⅠ	Lecture and discussion on the following topics: Brief description of pharmaceutical care and the pharmacists’ patient care process. Description of the general / major pathophysiology, signs, symptoms, monitoring, and therapies used in patients with osteoarthritis and gout. Brief review of the major drugs used in the treatment of osteoarthritis and gout with respect to use and efficacy and also to major adverse effects, drug interactions, and monitoring. Discussion of cases of patients with osteoarthritis and gout and the use of pharmaceutical care and the pharmacists’ patient care process into the care of those patients. AD-B-④-1、AD-B-⑤-1、AD-B-⑤-2、JB-(3)-①-1、JB-(3)-①-2、JB-(3)-②-1、JB-(3)-②-2、JB-(3)-②-3、JB-(3)-②-4、JB-(3)-③-1、JB-(3)-③-2、JB-(3)-③-3、JB-(3)-③-4
4	第4回	Pharmaceutical Care in Patients with Osteoarthritis and GoutⅡ	Lecture and discussion on the following topics: Brief description of pharmaceutical care and the pharmacists’ patient care process. Description of the general / major pathophysiology, signs, symptoms, monitoring, and therapies used in patients with osteoarthritis and gout. Brief review of the major drugs used in the treatment of osteoarthritis and gout with respect to use and efficacy and also to major adverse effects, drug interactions, and monitoring. Discussion of cases of patients with osteoarthritis and gout and the use of pharmaceutical care and the pharmacists’ patient care process into the care of those patients. AD-B-④-1、AD-B-⑤-1、AD-B-⑤-2、JB-(3)-①-1、JB-(3)-①-2、JB-(3)-②-1、JB-(3)-②-2、JB-(3)-②-3、JB-(3)-②-4、JB-(3)-③-1、JB-(3)-③-2、JB-(3)-③-3、JB-(3)-③-4
5	第5回	Pharmacotherapeutic Considerations in Select Women’s Health Topics Ⅰ	Lecture and discussion on the following topics: Brief description of the menstrual cycle. Description of the types and relative effectiveness of contraceptives used in women Description of the major contraindications, warnings, and adverse effects, and select examples of estrogens, progestins, and intrauterine devices used as contraceptives. Description of appropriate prenatal care and the signs and symptoms and effective therapy for relatively common problems seen during pregnancy (nausea and vomiting, constipation, gastroesophageal reflux, preeclampsia). Brief description of the stages of fetal development and times when the fetus is at risk for teratogenicity. Description of the characteristics of drugs that lead to increased passage into the fetus and into breast milk and discussion of the possible adverse effects of drugs administered during pregnancy and breast feeding. AD-B-④-1、AD-B-⑤-1、AD-B-⑤-2、JB-(3)-①-1、JB-(3)-①-2、JB-(3)-②-1、JB-(3)-②-2、JB-(3)-②-3、JB-(3)-②-4、JB-(3)-③-1、JB-(3)-③-2、JB-(3)-③-3、JB-(3)-③-4
6	第6回	Pharmacotherapeutic Considerations in Select Women’s Health Topics Ⅱ	Lecture and discussion on the following topics: Brief description of the menstrual cycle. Description of the types and relative effectiveness of contraceptives used in women Description of the major contraindications, warnings, and adverse effects, and select examples of estrogens, progestins, and intrauterine devices used as contraceptives. Description of appropriate prenatal care and the signs and symptoms and effective therapy for relatively common problems seen during pregnancy (nausea and vomiting, constipation, gastroesophageal reflux, preeclampsia). Brief description of the stages of fetal development and times when the fetus is at risk for teratogenicity. Description of the characteristics of drugs that lead to increased passage into the fetus and into breast milk and discussion of the possible adverse effects of drugs administered during pregnancy and breast feeding. AD-B-④-1、AD-B-⑤-1、AD-B-⑤-2、JB-(3)-①-1、JB-(3)-①-2、JB-(3)-②-1、JB-(3)-②-2、JB-(3)-②-3、JB-(3)-②-4、JB-(3)-③-1、JB-(3)-③-2、JB-(3)-③-3、JB-(3)-③-4
7	第7回	Pharmacotherapy of Select Immune Disorders Ⅰ	Lecture and discussion on the following topics: Description of the general pathophysiology and the major signs and symptoms, drug and nondrug therapy, monitoring, and prognosis of rheumatoid arthritis, Crohn’s disease and ulcerative colitis, and psoriasis and psoriatic arthritis. Brief review of the major pharmacologic actions, adverse effects, and drug interactions of the small drug and biologic immunotherapies used in these disorders. Discussion of cases of patients with each disease and determination of appropriate therapy. AD-B-④-1、AD-B-⑤-1、AD-B-⑤-2、JB-(3)-①-1、JB-(3)-①-2、JB-(3)-②-1、JB-(3)-②-2、JB-(3)-②-3、JB-(3)-②-4、JB-(3)-③-1、JB-(3)-③-2、JB-(3)-③-3、JB-(3)-③-4
8	第8回	Pharmacotherapy of Select Immune DisordersⅡ	Lecture and discussion on the following topics: Description of the general pathophysiology and the major signs and symptoms, drug and nondrug therapy, monitoring, and prognosis of rheumatoid arthritis, Crohn’s disease and ulcerative colitis, and psoriasis and psoriatic arthritis. Brief review of the major pharmacologic actions, adverse effects, and drug interactions of the small drug and biologic immunotherapies used in these disorders. Discussion of cases of patients with each disease and determination of appropriate therapy. AD-B-④-1、AD-B-⑤-1、AD-B-⑤-2、JB-(3)-①-1、JB-(3)-①-2、JB-(3)-②-1、JB-(3)-②-2、JB-(3)-②-3、JB-(3)-②-4、JB-(3)-③-1、JB-(3)-③-2、JB-(3)-③-3、JB-(3)-③-4